Creative Planning Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Creative Planning boosted its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 4.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,938 shares of the company’s stock after acquiring an additional 995 shares during the quarter. Creative Planning’s holdings in Travere Therapeutics were worth $335,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its stake in shares of Travere Therapeutics by 912.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after buying an additional 1,995,419 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Travere Therapeutics by 79.2% in the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after purchasing an additional 81,611 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Travere Therapeutics in the first quarter valued at approximately $452,000. Acadian Asset Management LLC boosted its stake in shares of Travere Therapeutics by 202.6% in the second quarter. Acadian Asset Management LLC now owns 144,901 shares of the company’s stock valued at $1,190,000 after buying an additional 97,020 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after buying an additional 747,406 shares in the last quarter.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $19.85 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock’s 50-day moving average is $15.42 and its two-hundred day moving average is $10.51. The firm has a market cap of $1.55 billion, a P/E ratio of -4.36 and a beta of 0.70. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $19.92.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same period last year, the business earned ($1.17) earnings per share. On average, analysts anticipate that Travere Therapeutics, Inc. will post -4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Bank of America boosted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. upped their target price on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Canaccord Genuity Group reduced their target price on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, September 30th. Citigroup dropped their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Finally, HC Wainwright lowered their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.85.

Insider Transactions at Travere Therapeutics

In other news, CEO Eric M. Dube sold 21,125 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the transaction, the chief executive officer now owns 361,975 shares of the company’s stock, valued at $4,169,952. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, SVP William E. Rote sold 4,387 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the transaction, the senior vice president now owns 84,455 shares in the company, valued at $972,921.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric M. Dube sold 21,125 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the transaction, the chief executive officer now owns 361,975 shares of the company’s stock, valued at $4,169,952. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,707 shares of company stock valued at $1,504,312 in the last three months. 3.75% of the stock is owned by corporate insiders.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.